Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yuji Miura
Observed name:
Y. Miura
Institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
Observed institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
ORCID:
0000-0002-7091-628X
Observed ORCID:
0000-0002-7091-628X
OpenAlex ID:
A5121096150
Continuous administration of lenvatinib after first documented disease progression in patients with radioiodine-refractory thyroid cancer
2026
·
Naoki Fukuda
, Jumpei Yoshida
, et al.
·
Endocrine
·
1
Real-world platinum selection in immune checkpoint inhibitor-based therapy for recurrent or metastatic head and neck cancer: an exploratory multi-institutional retrospective study
2026
·
Jumpei Yoshida
, Naoki Fukuda
, et al.
·
Scientific Reports
·
1
PDF
Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer
2026
·
Yosuke Yasuda
, Soichiro Yoshida
, et al.
·
Japanese Journal of Clinical Oncology
·
1
Complete response to immune checkpoint blockade in sarcomatoid renal cell carcinoma with bone marrow metastasis: case report with tumor immune microenvironment profiling
2026
·
Yuji Miura
, Ryosuke Jikuya
, et al.
·
Journal for ImmunoTherapy of Cancer
Phase 2 study of ASP5541 (PRL-02), a long-acting intramuscular depot injection of abiraterone decanoate, in patients with advanced prostate cancer.
2026
·
Neal D. Shore
, Jose W. Avitia
, et al.
·
Journal of Clinical Oncology
PDF
A study of GSK5458514 administered alone or in combination with other anticancer agents in patients with prostate cancer.
2026
·
Benjamin Garmezy
, Gavin Chiu
, et al.
·
Journal of Clinical Oncology
PDF
54P Impact of treatment sequence between immune checkpoint inhibitors and paclitaxel/cetuximab in recurrent or metastatic head and neck cancer
2026
·
E. Toda
, J. Yoshida
, et al.
·
ESMO rare cancers.
PDF
590eP Underuse of adjuvant pembrolizumab in patients with renal cell carcinoma after nephrectomy: Real-world data from two cancer centers in Japan
2025
·
D. Nakama
, K. Takemura
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
8
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type